Adaptive Biotechnologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Adaptive Biotechnologies şirketinin toplam hissedar öz sermayesi $190.2M ve toplam borcu $133.6M olup, bu da borç-öz sermaye oranını 70.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $510.9M ve $320.6M dir.

Anahtar bilgiler

70.21%

Borç/özkaynak oranı

US$133.56m

Borç

Faiz karşılama oranı	n/a
Nakit	US$193.42m
Eşitlik	US$190.22m
Toplam yükümlülükler	US$320.63m
Toplam varlıklar	US$510.85m

Son finansal sağlık güncellemeleri

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15

Recent updates

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

May 07

Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge

Apr 10

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Mar 25 Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Feb 14

Adaptive Biotechnologies: Making Some Progress

Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Nov 26

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ADPT 'nin kısa vadeli varlıkları ( $256.5M ) kısa vadeli yükümlülüklerini ( $87.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: ADPT şirketinin kısa vadeli varlıkları ( $256.5M ) uzun vadeli yükümlülüklerini ( $232.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ADPT şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ADPT şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 70.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ADPT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ADPT tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/27 09:30
Gün Sonu Hisse Fiyatı	2025/05/27 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Adaptive Biotechnologies Corporation 11 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Derik de Bruin	BofA Global Research
Mark Massaro	BTIG
Daniel Leonard	Credit Suisse

Adaptive Biotechnologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Recent updates

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

Price target increased by 8.8% to US$10.57

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025

Adaptive Biotechnologies Corporation to Report Q1, 2025 Results on May 01, 2025

Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Independent Director notifies of intention to sell stock

Adaptive Biotechnologies Corporation Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Co-Founder recently sold US$1.6m worth of stock

Co-Founder notifies of intention to sell stock

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Full year 2024 earnings: EPS exceeds analyst expectations

Adaptive Biotechnologies Corporation to Report Q4, 2024 Results on Feb 11, 2025

Price target increased by 7.1% to US$7.58

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in Mrd Testing with Clonoseq and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies: Making Some Progress

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Senior VP notifies of intention to sell stock

Price target increased by 7.9% to US$6.83

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Price target decreased by 7.3% to US$6.33

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

New minor risk - Shareholder dilution

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Insufficient new directors

Co-Founder recently sold US$167k worth of stock

Adaptive Biotechnologies: A Post Earnings Assessment

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Consensus revenue estimates fall by 21%

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Consensus revenue estimates fall by 12%

Price target decreased by 15% to US$10.00

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Price target decreased by 8.0% to US$11.43

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Adaptive Biotechnologies Corporation Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Insufficient new directors

Chief Financial Officer notifies of intention to sell stock

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

New minor risk - Insider selling

Chief Financial Officer recently sold US$272k worth of stock

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology